Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519606 | 1.00 | ATM (0.55) | ATMALDH1A1GLAKMT2AL3MBTL1 | |
| SCHEMBL11147827 | 0.92 | ATM (0.53) | ATMALDH1A1GLAKMT2AL3MBTL1 | |
| SCHEMBL7400596 | 0.86 | ATM (0.57) | ATMALDH1A1GLAKMT2AL3MBTL1 | |
| SCHEMBL7381205 | 0.86 | ATM (0.57) | ATMALDH1A1GLAKMT2AL3MBTL1 | |
| SCHEMBL11148163 | 0.86 | ATM (0.57) | ATMALDH1A1GLAKMT2AL3MBTL1 | |
| SCHEMBL735799 | 0.85 | SLC1A3 (0.64) | KMT2AL3MBTL1MAPTSLC1A3SLC1A1 | |
| SCHEMBL334926 | 0.85 | SLC1A3 (0.64) | KMT2AL3MBTL1MAPTSLC1A3SLC1A1 | |
| SCHEMBL334927 | 0.85 | SLC1A3 (0.64) | KMT2AL3MBTL1MAPTSLC1A3SLC1A1 | |
| SCHEMBL9800497 | 0.83 | KMT2A (0.57) | ATMKMT2ACTSLCTSSCTSK | |
| SCHEMBL9828159 | 0.81 | HTT (0.58) | ATMALDH1A1GLAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161581-A1 | Novel aminoglycoside antibiotics effective against methicillin resistant staphylococcus auerus (mrsas) | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1710248-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTIC EFFECTIVE AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) | MEIJI SEIKA KAISHA LTD. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-0601909-B1 | Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof | ZAIDAN HOJIN BISEIBUTSU (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5618795-A | Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1997-04-08 | — | — | US | disclosed |
| US-5488038-A | Dibekacin derivatives and arbekacin derivatives active against resistant bacteria | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1996-01-30 | — | — | US | disclosed |
| EP-0601909-A2 | Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-4297485-A | Production of a selectively protected N-acylated derivative of an aminoglycosidic antibiotic | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161581-A1 | Novel aminoglycoside antibiotics effective against methicillin resistant staphylococcus auerus (mrsas) | RPS11, RPS18, MRPS17 | ATM 2016/4885ALDH1A1 2089/4885GLA 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.